MCID: DBT002
MIFTS: 41

Diabetic Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Name: Diabetic Autonomic Neuropathy 12 54 15 71
Diabetic Neuropathies 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11503
MeSH 43 D003929
NCIt 49 C27068
SNOMED-CT 67 50620007
UMLS 71 C0011882 C0271686

Summaries for Diabetic Autonomic Neuropathy

MalaCards based summary : Diabetic Autonomic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Autonomic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Quinapril and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord.

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 374)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.1 NTF3 NGF INS AKR1B1
2 microvascular complications of diabetes 5 32.2 INS AKR1B1 ACE
3 gastroparesis 30.7 MLNR MLN GAST
4 pure autonomic failure 30.5 REN EPO ACE
5 iritis 30.4 EPO ACE
6 neurogenic arthropathy 30.3 NGF INS
7 silent myocardial infarction 30.3 INS ACE
8 algoneurodystrophy 30.2 NGF INS
9 peptic esophagitis 30.1 MLN GAST
10 diabetic encephalopathy 30.1 NGF INS
11 pylorospasm 30.1 MLNR MLN
12 duodenal ulcer 30.0 MLN INS GAST
13 sensory peripheral neuropathy 30.0 NTF3 NGF AKR1B1
14 diabetic polyneuropathy 29.8 NTF3 NGF INS AKR1B1
15 polyneuropathy 29.8 NGF INS EPO AKR1B1 ACE
16 anorexia nervosa 29.7 PPY INS GCG
17 hypertension, diastolic 29.7 REN ACE
18 vascular disease 29.7 REN INS EPO ACE
19 peripheral vascular disease 29.6 INS GAST EPO ACE
20 sleep apnea 29.6 REN INS EPO ACE
21 microvascular complications of diabetes 3 29.5 REN INS AKR1B1 ACE
22 sleep disorder 29.4 REN INS ACE
23 diarrhea 29.3 SI REN MLN GAST
24 uremia 29.3 REN INS EPO ACE
25 nasopharyngitis 29.3 SI INS GCG
26 diabetes mellitus, ketosis-prone 29.3 SI INS GCG
27 end stage renal disease 29.3 REN INS EPO ACE
28 carbohydrate metabolic disorder 29.2 SI INS GCG
29 diabetic neuropathy 29.2 REN NTF3 NGF INS EPO AKR1B1
30 constipation 29.1 NTF3 MLNR MLN INS GCG GAST
31 apnea, obstructive sleep 28.9 REN INS GCG ACE
32 autonomic neuropathy 28.9 REN PPY NTF3 NGF MLNR MLN
33 congestive heart failure 28.9 REN INS EPO ACE
34 anuria 28.9 REN ACE
35 prediabetes syndrome 28.9 SI INS GCG ACE
36 orthostatic intolerance 28.9 REN EPO ADAM8 ACE
37 chronic kidney disease 28.8 REN INS EPO ACE
38 pheochromocytoma 28.7 REN NGF MLN EPO ACE
39 kidney disease 28.7 REN INS GCG EPO AKR1B1 ACE
40 diabetes mellitus 28.6 REN MLN INS GCG EPO AKR1B1
41 body mass index quantitative trait locus 11 28.3 REN MLN INS GCG AKR1B1 ACE
42 diabetes mellitus, type i 28.1 SI REN PPY INS GCG AKR1B1
43 peripheral nervous system disease 27.9 SI REN NTF3 NGF INS GCG
44 diabetes mellitus, noninsulin-dependent 27.4 SI REN PPY NGF INS GCG
45 microvascular complications of diabetes 2 11.4
46 neuropathy 11.2
47 abducens nerve disease 11.1
48 argyll robertson pupil 11.1
49 fainting 11.1
50 syncope 11.1

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:



Diseases related to Diabetic Autonomic Neuropathy

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:


sciatica, neuralgia

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
2
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
6
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
7
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
8
Capsaicin Approved Phase 4 404-86-4 1548943
9
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
10
Amitriptyline Approved Phase 4 50-48-6 2160
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Histamine Approved, Investigational Phase 4 51-45-6 774
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
leucovorin Approved Phase 4 58-05-9 6006 143
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Cetirizine Approved Phase 4 83881-51-0 2678
17
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
18
Donepezil Approved Phase 4 120014-06-4 3152
19
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
20
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
23
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
25
Cobalamin Experimental Phase 4 13408-78-1 6857388
26
protease inhibitors Phase 4
27 HIV Protease Inhibitors Phase 4
28 Antioxidants Phase 4
29 Protective Agents Phase 4
30 Antimetabolites Phase 4
31 Dopamine agonists Phase 4
32 Alpha-lipoic Acid Phase 4
33 Thioctic Acid Phase 4
34 Vitamin B 12 Phase 4
35 Vitamin B12 Phase 4
36 Vasodilator Agents Phase 4
37 Anesthetics Phase 4
38 Anesthetics, Local Phase 4
39 Amitriptyline, perphenazine drug combination Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Histamine Antagonists Phase 4
42 Anti-Allergic Agents Phase 4
43 Histamine H1 Antagonists Phase 4
44
Histamine Phosphate Phase 4 51-74-1 65513
45 Hypolipidemic Agents Phase 4
46 Anticholesteremic Agents Phase 4
47 Lipid Regulating Agents Phase 4
48 Citrate Phase 4
49 Vitamin B 6 Phase 4
50 Analgesics, Non-Narcotic Phase 4

Interventional clinical trials:

(show top 50) (show all 394)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
5 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
6 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
7 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
8 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
9 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
10 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
11 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
12 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
13 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
14 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
15 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
16 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
17 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
18 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
19 Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients Completed NCT01102699 Phase 4 Filgrastim, hrG-CSF
20 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
21 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
22 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
23 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
24 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
25 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
26 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
27 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
28 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
29 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
30 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
31 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
32 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
33 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
34 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
35 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
36 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
37 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
38 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
39 RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
40 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Recruiting NCT04246619 Phase 4 Pregabalin;Duloxetine
41 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Not yet recruiting NCT04193566 Phase 4 Forxiga
42 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
43 A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Terminated NCT02156336 Phase 4 Ranolazine;Placebo
44 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
45 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
46 A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin. Withdrawn NCT03640221 Phase 4 Ertugliflozin;Hydrochlorothiazide 12.5mg
47 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
48 Diabetic Neuropathic Pain Topical Treatment- Comparative Study Unknown status NCT00661063 Phase 3 ketamine;vehicle gel;ketamine + clonidine;clonidine gel 1%
49 Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Unknown status NCT01125215 Phase 2, Phase 3 0.75% capsaicin nanoparticle cream;Placebo
50 A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy Unknown status NCT00134524 Phase 3

Search NIH Clinical Center for Diabetic Autonomic Neuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cochrane evidence based reviews: diabetic neuropathies

Genetic Tests for Diabetic Autonomic Neuropathy

Anatomical Context for Diabetic Autonomic Neuropathy

MalaCards organs/tissues related to Diabetic Autonomic Neuropathy:

40
Heart, Testes, Spinal Cord, Skin, Bone, Brain, Bone Marrow

Publications for Diabetic Autonomic Neuropathy

Articles related to Diabetic Autonomic Neuropathy:

(show top 50) (show all 1033)
# Title Authors PMID Year
1
Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. 61 54
11245210 2001
2
Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. 54 61
9647338 1998
3
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. 61 54
18370475 1998
4
An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. 54 61
8088110 1994
5
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 61 54
8299441 1993
6
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. 54 61
8482988 1993
7
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. 61 54
2123430 1990
8
Modeling Hypoxia-Induced Neuropathies Using a Fast and Scalable Human Motor Neuron Differentiation System. 61
32386561 2020
9
Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. 61
32400192 2020
10
Stem Cell Therapies for the Treatment of Diabetic Neuropathies: Future Perspectives. 61
32303173 2020
11
Spectrum of diabetic neuropathies. 61
32206478 2020
12
Assessment of cutaneous axon-reflex responses to evaluate functional integrity of autonomic small nerve fibers. 61
32125538 2020
13
Clinical Impact of Atypical Chest Pain and Diabetes Mellitus in Patients with Acute Myocardial Infarction from Prospective KAMIR-NIH Registry. 61
32059609 2020
14
Autonomic Peripheral Neuropathy. 61
31996622 2020
15
Diabetic autonomic neuropathy of the gastrointestinal tract. 61
32550939 2020
16
Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. 61
31625779 2019
17
Commentary: Recognizing pupillary dysfunction in diabetic autonomic neuropathy. 61
31332119 2019
18
Commentary: Abnormal pupillary light reflexes - A sign of diabetic autonomic neuropathy. 61
31332118 2019
19
Association of pupil responses with severity of erectile dysfunction in diabetes mellitus. 61
31332117 2019
20
Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. 61
31456118 2019
21
Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy. 61
31592273 2019
22
Diabetic neuropathies influence recovery from hip-fracture surgery in older persons with diabetes. 61
30738920 2019
23
Painful and Painless Diabetic Neuropathies: What Is the Difference? 61
31065863 2019
24
Omega-3 polyunsaturated fatty acids exert anti-oxidant effects through the nuclear factor (erythroid-derived 2)-related factor 2 pathway in immortalized mouse Schwann cells. 61
30216708 2019
25
Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. 61
30935671 2019
26
Uncoupling neurotrophic function from nociception of nerve growth factor: what can be learned from a rare human disease? 61
30632491 2019
27
Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy. 61
30568127 2019
28
Droxidopa for Hypotension of Different Etiologies: Two Case Reports. 61
30828233 2019
29
Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. 61
31341662 2019
30
['Point of no return' in diabetic neuropathies: a dangerous delusion]. 61
31626177 2019
31
Diagnostic accuracy of composite autonomic symptom scale 31 (COMPASS-31) in early detection of autonomic dysfunction in type 2 diabetes mellitus. 61
31564941 2019
32
Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy. 61
30084083 2018
33
Altered pain processing in people with type I and II diabetes: a protocol for a systematic review and meta-analysis of pain threshold and pain modulation mechanisms. 61
30518431 2018
34
Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats. 61
30372853 2018
35
Diabetic autonomic neuropathy resulting in sexual dysfunction. 61
30256272 2018
36
Ethnic variation of IL-4 intron 3 VNTR gene polymorphism; its association with type 2 diabetes mellitus and its complication (neuropathy) in Egyptian subjects. 61
30318704 2018
37
The relationship of one-leg standing time with peripheral nerve function and clinical neuropathy in patients with type 2 diabetes. 61
30603374 2018
38
Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. 61
30179216 2018
39
Inflammatory Diabetic Neuropathy: Helpful Diagnostic Parameters. 61
30124555 2018
40
Autonomic disturbances in diabetes: Assessment and anaesthetic implications. 61
30166651 2018
41
Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. 61
29091313 2018
42
Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients. 61
29458425 2018
43
Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. 61
29108839 2018
44
Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. 61
29693021 2018
45
Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center. 61
30576362 2018
46
[Diabetic and non-diabetic neuropathies in patients with diabetes mellitus]. 61
29863704 2018
47
Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. 61
28623420 2017
48
Assessment of diabetic neuropathy with emission tomography and magnetic resonance spectroscopy. 61
28234786 2017
49
Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation. 61
28178976 2017
50
Role of "Sural Sparing" Pattern (Absent/Abnormal Median and Ulnar with Present Sural SNAP) Compared to Absent/Abnormal Median or Ulnar with Normal Sural SNAP in Acute Inflammatory Demyelinating Polyneuropathy. 61
29085327 2017

Variations for Diabetic Autonomic Neuropathy

Expression for Diabetic Autonomic Neuropathy

Search GEO for disease gene expression data for Diabetic Autonomic Neuropathy.

Pathways for Diabetic Autonomic Neuropathy

Pathways related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.24 REN NTF3 NGF INS ACE
2
Show member pathways
11.18 REN INS GCG ACE

GO Terms for Diabetic Autonomic Neuropathy

Cellular components related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 REN PPY NTF3 NGF MLN INS
2 extracellular space GO:0005615 9.36 REN PPY NTF3 NGF INS GCG
3 endosome lumen GO:0031904 9.16 NGF INS

Biological processes related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.8 PPY MLNR MLN INS GCG GAST
2 negative regulation of neuron apoptotic process GO:0043524 9.61 NTF3 NGF ADAM8
3 nerve development GO:0021675 9.4 NTF3 NGF
4 amyloid-beta metabolic process GO:0050435 9.37 REN ACE
5 nerve growth factor signaling pathway GO:0038180 9.26 NTF3 NGF
6 angiotensin maturation GO:0002003 9.16 REN ACE
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.13 NTF3 NGF GCG
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 8.8 NTF3 INS EPO

Molecular functions related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 REN NTF3 NGF GCG
2 insulin-like growth factor receptor binding GO:0005159 9.16 REN INS
3 hormone activity GO:0005179 9.1 PPY MLN INS GCG GAST EPO
4 nerve growth factor receptor binding GO:0005163 8.96 NTF3 NGF

Sources for Diabetic Autonomic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....